Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer

Current Medical Research and Opinion

Volumn 30, Issue 2, 2014, Pages 321-328

  Cartwright, T ^a   Chao, C ^b   Lee, M ^b   Lopatin, M ^b   Bentley, T ^c   Broder, M ^c   Chang, E ^c  

^a Ocala Oncology   (United States)

^b Genomic Health Inc   (United States)

^c PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

Author keywords

Biomarker; Chemotherapy; Clinical utility; Oncotype DX recurrence score; Physician survey

Indexed keywords

OXALIPLATIN; ANTINEOPLASTIC AGENT;

12 GENE COLON CANCER RECURRENCE SCORE ASSAY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL OBSERVATION; COLON CANCER; COMORBIDITY; GENETIC ANALYZER; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ONCOLOGIST; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NORMAL HUMAN; PREDICTIVE VALUE; RECURRENCE RISK; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT PLANNING; ADJUVANT CHEMOTHERAPY; CLINICAL PRACTICE; COLONIC NEOPLASMS; FEMALE; GENETIC SCREENING; GENETICS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINE; QUESTIONNAIRE; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; GENETIC TESTING; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 84893303746     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.855183     Document Type: Article

References (42)

1. National Cancer Institute: Colon and Rectal Cancer. National Institutes of Health. Available at: Http://www.cancer.gov/cancertopics/types/colon- Andrectal. Accessed 28 Oct 2013
2. National Comprehensive Cancer Network-. NCCN clinical practice guidelines in oncology (NCCN Guidelines-): Colon cancer. Version 1.2014. Fort Washington, PA: National Comprehensive Cancer Network. 2013. Available at: Http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed 28 Oct 2013
3. Yothers G, OConnell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29:3768-74
4. Tournigand C, AndréT, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012;30:3353-60
5. OConnor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011;29:3381-8
6. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 2004;22:1797-806
7. QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomized study. Lancet 2007;370:2020-9
8. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872-7
9. Edge SB, Byrd DR, Compton CC, et al, editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010
10. Gunderson LL, Jessup JM, Sargent DJ, et al. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28:264-71
11. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57
12. Sargent DJ, Marsoni S, Thibodeau SN, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 2008;26:15s (Suppl; abstr 4008
13. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219-26
14. Chapuis PH, Dent OF, Fisher R, et al. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985;72:698-702
15. Griffin MR, Bergstralh EJ, Coffey RJ, et al. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 1987;60:2318-24
16. Scott NA, Wieand HS, Moertel CG, et al. Colorectal cancer. Dukes stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg 1987;122:1375-9
17. Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 1988;31:33-41
18. Bö ttger TC, Potratz D, Stö ckle M, et al. Prognostic value of DNA analysis in colorectal carcinoma. Cancer 1993;72:3579-87
19. Jessup JM, Lavin PT, Andrews CW, et al. Sucrase-isomaltase is an independent prognostic marker for colorectal carcinoma. Dis Colon Rectum 1995;38:1257-64
20. DEredita G, Serio G, Neri V, et al. A survival regression analysis of prognostic factors in colorectal cancer. Aust N Z J Surg 1996;66:445-51
21. Jessup JM, McGinnis LS, Steele Jr. GD, et al. The National Cancer Data Base report on colon cancer. Cancer 1996;78:918-26
22. Payne JE, Meyer HJ. Independently predictive prognostic variables after resection for colorectal carcinoma. Aust N Z J Surg 1997;67:849-53
23. OConnell MJ, Lavery IC, Gray RG, et al. Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. J Clin Oncol 2010;28:15s (Suppl; abstr 3503
24. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011;29:4611-9
25. Roth AD, Tejpar S, Yan P, et al. Correlation of molecular markers in colon cancer with stage-specific prognosis: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 2009;27:15s (Suppl; abstr 4002
26. Venook AP, Niedzwiecki D, Lopatin M, et al. Validation of a 12-gene colon cancer recurrence score (RS) in patients ( pts) with stage II colon cancer (CC) from CALGB 9581. J Clin Oncol 2011;29:15s (Suppl; abstr 3518
27. Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 2008;51:503-7
28. Harris EI, Lewin DN, Wang HL, et al. Lymphovascular invasion in colorectal cancer: An interobserver variability study. Am J Surg Pathol 2008;32:1816-21
29. Oonnell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of stage II/III colon cancer patients treated with surgery alone or surgery plus adjuvant 5-FU/LV. J Clin Oncol 2010;28:3937-44
30. Niedzwiecki D, Bertagnolli MM, Warren RS, et al. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: Results from CALGB 9581. J Clin Oncol 2011;29:3146-52
31. Srivastava G, Renfro LA, Behrens RJ, et al. Prospective evaluation of a 12-gene assay on treatment recommendations in stage II colon cancer patients. Poster presented at ASCO Gastrointestinal Cancers Symposium, 2013 Jan16-18, San Francisco, CA
32. Krzyzanowska MK, Regan MM, Powell M, et al. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. J Am Coll Surg 2009;208:202-9
33. Interactive Clinical Intelligence. OncoReport: Medical Oncology T3. Dublin, OH: Cardinal Health. 2010. Available at: Http://www.icimrr.com/. Accessed 28 Oct 2013
34. OConnell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-5
35. Parsons HM, Tuttle TM, Kuntz KM, et al. Association between lymph node evaluation for colon cancer and node positivity over the past 20 years. JAMA 2011;306:1089-97
36. Shak S, Baehner FL, Stein M, et al. Quantitative gene expression analysis in a large cohort of estrogen-receptor positive breast cancers: Characterization of the tumor profiles in younger patients (-40 years) and in older patients (-70 years). Cancer Res 2010;70:24s (Suppl; abstr P3-10-01
37. Meropol NJ, Lyman GH, Chien R, et al. Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: Impact of quality-Adjusted life expectancy and costs. J Clin Oncol 2011;29:4s (Suppl; abstr 491
38. Aballéa S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007;109:1082-9
39. Carlson B. Putting a lid on chemotherapy costs. Biotechnol Healthc 2011;8:15-18
40. Oratz R, Kim B, Chao C, et al. Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract 2011;7:94-9
41. Schonlau M, Fricker RD, Elliott MN. Conducting research surveys via e-mail and the web. Santa Monica, CA: RAND Corporation, 2002. Available at: Http:// www.rand.org/pubs/monograph-reports/MR1480. Accessed 29 Oct 2013
42. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002;20:3999-4005